BiotechTube

enzalutamide + rifampin

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Drug-Drug Interaction (DDI)

Conditions

Drug-Drug Interaction (DDI), Healthy Subjects, Pharmacokinetics of Enzalutamide

Trial Timeline

Jul 1, 2013 → Sep 1, 2013

NCT ID
NCT02138799

About enzalutamide + rifampin

enzalutamide + rifampin is a phase 1 stage product being developed by Astellas Pharma for Drug-Drug Interaction (DDI). The current trial status is completed. This product is registered under clinical trial identifier NCT02138799. Target conditions include Drug-Drug Interaction (DDI), Healthy Subjects, Pharmacokinetics of Enzalutamide.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT02138799Phase 1Completed

Competing Products

15 competing products in Drug-Drug Interaction (DDI)

See all competitors
ProductCompanyStageHype Score
EC905 + verapamilAstellas PharmaPhase 1
33
rosuvastatin + fidaxomicinAstellas PharmaPhase 1
33
ASP3652 + Gemfibrozil + RepaglinideAstellas PharmaPhase 1
33
napabucasin + cytochrome P450 (CYP450) probe drugs or BCRP transporter substrateSumitomo PharmaPhase 1
33
Pyrotinib Maleate + EfavirenzJiangsu Hengrui MedicinePhase 1
33
SHR3680 + digoxin + Rosuvastatin calcium + metformin hydrochlorideJiangsu Hengrui MedicinePhase 1
33
Rifampin + SHR1459Jiangsu Hengrui MedicinePhase 1
33
fostamatinib + Microgynon® 30 (Oral contraceptive) + PlaceboAstraZenecaPhase 1
33
BMS-986020 + Montelukast + Flurbiprofen + DigoxinBristol Myers SquibbPhase 1
32
Simvastatin + VoclosporinAurinia PharmaceuticalsPhase 1
28
Omeprazole 40 MG + Famotidine 40 mg + Telotristat ethyl 250 mgLexicon PharmaceuticalsPhase 1
28
pitavastatin + pitavastatin single dose combined with ceftobiproleBasilea PharmaceuticaPhase 1
28
elafibranor + CHRONO-INDOCIDGenfitPhase 1
25
Raxone (idebenone 150 mg) + Midazolam 2,5 mgSanthera PharmaceuticalsPhase 1
25
Midazolam 5mg Syrup + Vapendavir 264 mg BID + Vapendavir 528 mg QDVaxartPhase 1
25

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85